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osting by EAbstract Purpose: To evaluate the safety, functional and anatomical effects of intravitreal
Avastin (bevacizumab) in treatment of recent retinal venous occlusion.
Design: Prospective interventional series non-comparative study.
Setting: Department of Ophthalmology, Faculty of Medicine, El-Minia University, Egypt.
Methods: The study included 30 eyes of 30 patients with recent retinal venous occlusion of less than
3 months duration 12 eyes (40%) of patients with central retinal vein occlusion (CRVO) and 18 eyes
(60%) with branch retinal vein occlusion (BRVO) were injected with intravitreal bevacizumab
1.25 mg (0.05 ml) of commercially available bevacizumab [Avastin; Genentech, Inc., San Francisco,
CA] at a concentration of 25 mg/ml as a primary treatment. The mean number of injections was 2.7
(range, 1–6 injections) 6–8 weeks intervals and follow-up for 12 months (range, 9–13 months).
Patients underwent visual acuity testing (VA) as functional assessment. Anatomically, optical
coherence tomography (OCT) is used for measurement of central retinal thickness (CRT) to detect
macular edema (ME), fundus photography and ﬂuorescein angiography (FA) to detect venous tor-
tuosity, optic disc edema and surface wrinkling rather than ME. All ﬁnding at baseline and each
follow-up visit were reported.
Results: The mean age of all patients was 65.3 years ± 8.5 (range, 55–82 years), 20 males and 10
females patients. The mean baseline VA was 20/240 (log MAR 1.08 ± 0.52) and improved to 20/r. Abdulrahman Al-Mishary
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.
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ity. All rights reserved. Peer-
d University.
lsevier
88 S.A. Mehany et al.60 (log MAR 0.48 ± 0.32) with statistically signiﬁcance difference change (P< 0.001). The mean
baseline CRT was 455 lm± 126 (range, 386–510), decreased to 356 lm± 118 (range, 296–416)
after 1 month with statistically signiﬁcance difference change (P< 0.02) and to 402 lm± 170
(range, 338–468) after 6 months (P< 0.067) and to 250 lm± 48 (range, 200–298) at last follow-
up with statistically signiﬁcance difference change from the baseline (P< 0.001). There were great
proportional decrease in venous tortuosity, optic disc edema and surface wrinkling after 1 month of
injection. Neither systemic nor intraocular adverse events were reported.
Conclusions: Intravitreal Avastin (IVA) is safe well tolerated, effectively improve VA, fundus pic-
ture and stabilize anterior segment neo-vascular activity in patients with recent retinal venous occlu-
sion.
ª 2010 King Saud University. All rights reserved.1. Introduction
Retinal vein occlusions (RVOs) disease is not uncommon and
remains the second most common sight-threatening vascular
disorder following diabetic retinopathy (Central Vein Occlusion
Study Group, 1997). The incidence of CRVO is currently re-
ported as 1.8% (Klein et al., 2008). The treatment of macular
edema in this condition remains challenging and controversial.
At the present time, the therapeutic efforts for sustained func-
tional improvement remain limited. Despite concerted efforts
to treat patients both medically and surgically, no clear con-
sensus on a treatment modality or guidelines have emerged
since the branch vein occlusion (BVO) and central vein occlu-
sion (CVO) studies (Alexander and Netan, 2008). RVOs cause
decreased tissue perfusion and increased hydrostatic pressure
within the involved segments as a consequence of vascular
obstruction. This leads to a constellation of ﬁndings including
intraretinal hemorrhages, exudation of ﬂuid and varying levels
of ischemia, surface wrinkling retinopathy, and possible devel-
opment of neo-vascular complications (Hayreh, 1983).
Several therapeutic methods are used to treat the macular
edema secondary to BRVO (Rehak and Rehak, 2008;
Hoerauf, 2007; McIntosh et al., 2007). Although macular grid
laser photocoagulation was initially recommended based on
the results of the (BVOS) (The Branch Vein Occlusion Study
Group, 1984). Later studies suggested that the improvement
of visual function by this treatment was limited (Battaglia
et al., 1999a,b). Unfortunately, the CVOS showed no beneﬁt
of macular grid laser treatment on CME due to CRVO.
Accordingly, investigators have looked at other approaches
to treat CME due to BRVO and CRVO, including laser-
induced chorioretinal anastamosis, radial optic neurotomy,
arteriovenous sheathotomy, intravitreal tissue plasminogen
activator and therapy with intravitreal steroids or anti-vascu-
lar endothelial growth factor (VEGF) agents such as Pegapta-
nib sodium (Macugen, Eyetech/Pﬁzer), Ranibizumab
(Lucentis, Genentech), or bevacizumab (Avastin, Genentech).
Intravitreal injection of corticosteroids (triacinolone aceto-
nide) has been reported to be effective for the macular edema
secondary to RVOs (Jonas et al., 2005; Avitabile et al., 2005).
However, this therapy is often associated with cataract forma-
tion and elevation of intraocular pressure especially if repeated
injections are required (Ozkiris et al., 2006; Cekic et al., 2005).
The results of recent studies (Noma et al., 2008, 2006) have
shown that the level of vasopermeability factors, including vas-
cular endothelial growth factor, was signiﬁcantly increased in
the vitreous of patients with RVOs. In addition, it has been
shown that an intravitreal injection of bevacizumab (Avastin,Genentech, Inc., San Francisco, CA), a full-length recombinant
monoclonal antibody against human vascular endothelial
growth factor (VEGF), is effective in reducing the macular ede-
ma that develops in eyes with RVOs (Kreutzer et al., 2008;
Chung et al., 2008; Kriechbaum et al., 2008; Wu et al., 2008;
Spandau et al., 2007; Rabena et al., 2007; Costa et al., 2004).
Thus, the inhibition of vascular endothelial growth factor by
bevacizumab injection has become an alternative treatment for
the macular edema secondary to RVOs. A favorable short term
studies to intravitreal Avastin (IVA) injection suggest a possible
role of VEGF in RVOs. However, there are very few reports on
the long-term results of this treatment (Jaissle et al., 2009; Prager
et al., 2009).
The purposes of this study were to evaluate the results of
12 months after intravitreal bevacizumab therapy regarding
to safety, functional and anatomical effects in treatment of
recent retinal venous occlusions.
2. Patients and methods
This prospective interventional series non-comparative study
included 30 eyes of 30 patients with recent RVOs (less than
3 months in duration). Twelve eyes (40%) had CRVO and
18 (60%) had BRVO. All patients fulﬁlled the following inclu-
sion criteria: recent onset with no previous treatment for RVO,
non-ischemic type (less than 10 disc diameter of non-perfusion
in CRVO and less than 5 disc diameter of non-perfusion in
BRVO). All patients had baseline clinical examinations, which
included a Snellen visual acuity test, intraocular pressure mea-
surement using applanation tonometry, slit lamp examination
of the anterior segment, fundus biomicroscopy with Volk 90
and 78 diopters lenses, dilated fundus examination with indi-
rect ophthalmoscopy and fundus photography and ﬂuorescein
angiography. Optical coherence tomography (OCT) was per-
formed for all of patients. Stratus OCT3 (Carl Zeiss Meditec,
Dublin, CA) was performed. Readings for 1 mm central retinal
thickness (CRT) were obtained from the mean retinal thick-
ness in the central subﬁeld using six linear scans 6 mm long
centered on ﬁxation and processed as a retinal map.
In all patients, the intravitreal injection of off label bev-
acizumab was performed in a standard protocol in the operat-
ing theater under operating ophthalmoscope and complete
aseptic condition after obtaining informed consent. Topical
0.4% benoxinate hydrochloride was applied to the ocular sur-
face followed by scrubbing of the eye lids and lashes with 10%
of povidone iodine and conjunctiva installed with 5% povi-
done iodine three times several minutes apart. A sterile eyelid
speculum was used for all injections, sub-conjunctival 1 cc
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the inferotemporal quadrant. Bevacizumab was injected
through the pars plana 3.5–4.0 mm posterior to the surgical
limbus using a 30-gauge needle at a dose of 1.25 mg in
0.05 ml. Post-injection, a sterile cotton swab is placed at the
site of injection to prevent reﬂux of vitreous or drug, light per-
ception was assessed and indirect ophthalmoscope to see optic
nerve head perfusion. The intraocular pressure (IOP) was
monitored until it decreased below 30 mm Hg if it is elevated
after injection.
After the injection, the patients were instructed to apply
topical antibiotics to the injected eye four times a day for
5 days. Postoperative follow-up included repeated clinical
examinations and OCT to all of the patients. Patients were as-
sessed for adverse events including elevated intraocular pres-
sure, cataract progression, retinal detachment, post-injection
inﬂammation, and endophthalmitis. Follow-up evaluations
were scheduled to next day, 1 week then monthly till the end
of follow-up. A repeated injection of bevacizumab was per-
formed for persistent or recurrent macular edema (ME) seen
by ﬂuorescein angiography documented by OCT and clinically
drop of visual acuity measurements.
Treatment success was evaluated by either CRT of
6260 lm or best corrected visual acuity (BCVA) of 20/40
(0.30 log MAR) or better, those patients no further injection
were needed. Borderline improvement (ﬂ in CMT by at least
50 lm from the baseline OCT measurement) and non-
improved patients with persistent or recurrent macular edema
were scheduled for further injections.
Statistical analysis was assessed using (SPSS, version 13,
SPSS, Inc., Chicago, Illinois, USA). All variables were
expressed as mean ± standard deviation (SD), the paired
Student t-test was used and P value 6 0.05 was considered
statistically signiﬁcant. Snellen’s BCVA measurements were
converted to logarithmic minimal angle resolution (log MAR)
equivalents to perform the statistical analysis. Main outcome
measures changes in BCVA and CMT, secondary outcome
are the adverse effects and the need for re-injection.Figure 1 (A) OCT of a case of CRVO at baseline with › CRT and sp
with marked resolution of CME; (C) OCT of the same case at the en
Figure 2 (A) OCT of a case of superior temporal BRVO at baselin
(6 months); (C) OCT of the same case at the end of follow-up (succes3. Results
Thirty eyes of 30 patients received intravitreal Avastin (IVA)
injection in this study. Out of them 12 eyes (40%) with central
retinal vein occlusion (CRVO) (Fig. 1) and 18 eyes (60%) with
branch retinal vein occlusion (BRVO) (Figs. 2–5). The mean
age of all patients was 65.3 years ± 8.5 (range, 55–82 years),
20 males and 10 females patients. All of patients were of
non-ischemic type with recent retinal venous occlusion less
than 3 months (range, 1 day to 3 months). Follow-up period
was 12 months (range, 9–13 months). At the baseline OCT
demonstrate increasing in the 1-mm central retinal thickness
(CRT) in all of the studied eyes in which the mean CRT was
455 ± 126 lm (range, 386–510) due to marked macular ede-
ma, often with cystoid spaces seen clinically as well as docu-
mented by OCT, decreased to a mean of 280 ± 72 lm
(range, 240–340) after 1 week of injection with a difference
of 175 lm from the baseline and this is highly signiﬁcant differ-
ence (P< 0.01) (Table 1, Fig. 6).
The mean CRT increased again to 356 ± 118 lm (range,
296–416) after 1 month of injection with a difference of
99 lm from the baseline and still signiﬁcantly different
(P< 0.02). At 3 months the mean CRT decreased again to
302 ± 86 lm (range, 270–368) with a difference of 153 lm
from the baseline and still signiﬁcantly different (P< 0.01).
The marked increasing again of the mean CRT on the
follow-up period was seen at 6 months in which it was
402 ± 170 lm (range, 338–468) with the little difference from
mean baseline which was 53 lm difference due recurrence of
macular edema, and it was not signiﬁcant from the baseline
(P< 0.067). At 12 months the mean CRT decreased to lowest
level which it was 250 ± 48 lm (range, 200–298) with the high-
est signiﬁcantly difference from the mean baseline, in which the
difference was highest, 205 lm (P< 0.001) (Table 1, Fig. 6).
The mean best corrected visual acuity (BCVA) revealed sig-
niﬁcant improvement at all time points compared with baseline
and continued to improve all over the study with repeated
injections (Table 1, Fig. 7). At baseline the mean BCVA wasonge like CME; (B) OCT of the same case after 3 (IVA) injections
d of follow-up (successful treatment).
e with CME; (B) OCT of the same case after two IVA injections
sful treatment).
Figure 3 (A) Lt., inferior temporal BRVO, red free fundus photography; (B) Lt., inferior temporal BRVO, FA showing Fl. dye leakage
of ME; (C) Lt., inferior temporal BRVO, red free same case 6 months after IVA injection; (D) Lt., inferior temporal BRVO, FA, same
case 6 months after IVA injection; (E) OCT, of the same case at baseline showing › CMT due to CME; (F) OCT, with initial resolution of
CME and ﬂ CMT 1 week of IVA injection; (G) OCT showing recurrence of CME 6 months after ﬁrst injection; (H) OCT of the same case
at the end of follow-up with successful resolution of CME.
Figure 4 (A) Fundus photography and FA of a case of Lt.,
superior macular BRVO showing retinal Hge, cotton wool spots,
exudates and surface wrinkling maculopathy seen next day of
occlusion.
Figure 5 (A) FA, of Lt., upper temporal BRVO at baseline; (B)
OCT of the same case with ME and › CRT at baseline; (C) FA, of
the same case 1 month after ﬁrst IVA injection (ﬂ ME and retinal
hemorrhage); (D) OCT of the same case with resolution of ME
and ﬂ CRT at 1 month after ﬁrst IVA injection.
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1 week after injection and still the same up to 1 month postop-
eratively (P< 0.001). At 3 months the mean BCVA changed
to 20/100 (log MAR 0.70) due to recurrence of macular edema
in some eyes but still signiﬁcantly different than baseline
(P< 0.01). At 6 months the mean BCVA signiﬁcantly im-
proved again to 20/80 (log MAR 0.60) (P< 0.001). At the
end of follow-up (about 12 months) further signiﬁcant
improvement to 20/60 (log MAR 0.48) (P< 0.001), about
halving the baseline visual angle.
At the baseline there were 18 eyes (60%) of all patients had
BCVA of less than 20/240, 9 eyes (30%) had BCVA of (range,
20/240–20/50) and 3 eyes (10%) had BCVA of more than (20/
50). At the end of follow-up 6 eyes (20%) of all patients had
BCVA of less than 20/240, 18 eyes (60%) had BCVA of (range,
20/240–20/50) and 6 eyes (20%) had BCVA of more than (20/
50) (Table 3, Fig. 8).
Table 2 demonstrating the number of intravitreal Avastin
(IVA) injections all over the study period. The total number
of injections was 81 with a mean of 2.7 (range, 1–6 injections)
6–8 weeks interval, 41 injections (mean 3.4) in CRVO eyes, 40
injections (mean 2.2) in BRVO eyes. Twelve eyes (40%) had 3
injections, 12 eyes (40%) had 2 injections, 2 eyes (6.7%) had
1 injection those had BRVO. Four eyes (13.3%) had more
than 3 injections those had CRVO, out of them 2 eyes had
4 injections, 1 eye 5 injections and 1 eye 6 injections.
There were great proportional decrease in venous tortuos-
ity, optic disc edema and surface wrinkling after 1 month of
injection. No evidence of increase foveal a vascular zone dem-
onstrated by (FA), no neo-vascularization. Neither systemic
nor intraocular adverse events were reported except mild de-
gree of sub-conjunctival hemorrhage in 5 eyes that resolved
spontaneously within 5 days of injection.4. Discussion
Retinal vein occlusions are the second most common form of
retinal vascular disease with a prevalence of 0.5–1.0% (Klein
et al., 2000). Depending on the location of the occlusion and
the extent of non-perfusion, the vision threatening complica-
tions of retinal vein occlusions include neo-vascularization of
the retina or optic nerve causing recurrent vitreous hemor-
Table 1 Mean CRT and mean BCVA at baseline and follow-up.
Timing Mean (SD) {range} CMT (lm) Dif. CMT (lm) P value Mean BCVA log MAR (SD) P value
Baseline 455 (±126) {386–510} 20/240 1.08 (±0.52)
1 week 280 (±72) {240–340} 175 <0.01 20/50 0.40 (±0.25) <0.0001
1 month 356 (±118) {296–416} 99 <0.02 20/50 0.40 (±0.27) <0.0001
3 months 302 (±86) {270–368} 153 <0.01 20/100 0.70 (±0.30) <0.001
6 months 402 (±170) {338–468} 53 <0.06 20/80 0.60 (±0.42) <0.001
12 months 250 (±48) {200–298} 205 <0.001 20/60 0.48 (±0.32) <0.0001
P value considered to be statistically signiﬁcant if it is <0.05.
Figure 6 The mean CRT in lm measured with OCT.
Figure 7 Visual acuity in log MAR in over time.
Early Avastin management in acute retinal vein occlusion 91rhage, neo-vascular glaucoma, macular ischemia, macular ede-
ma, surface wrinkling retinopathy, capillary non-perfusion,
and intraretinal hemorrhage. The endogenous production ofvascular endothelial growth factor (VEGF) has been impli-
cated as an etiologic factor for several of these complications
(Pe’er et al., 1995).
Figure 8 BCVA improvement with follow-up time.










1 injection 0 2 2 (6.7%)
2 injections 2 10 12 (40%)
3 injections 6 6 12 (40%)
4 injections 2 0 2 (6.7%)
5 injections 1 0 1 (3.3%)
6 injections 1 0 1 (3.3%)
Total number
of injection (mean)
41 (3.4) 40 (2.2) 81 (2.7)
Table 3 BCVA improvement with follow-up time.
Timing BCVA Number of eyes Percentage (%)
Baseline (1) ﬂ 20/240 18 60
(2) 20/240–20/50 9 30
(3) › 20/50 3 10
At 12 months (1) ﬂ 20/240 6 20
(2) 20/240–20/50 18 60
(3) › 20/50 6 20
92 S.A. Mehany et al.Vascular endothelial growth factor (VEGF) has been impli-
cated as the major factor responsible for increased vascular
permeability and ME in CRVO. Vascular endothelial growth
factor was shown to be up-regulated in human eyes with
CRVO (Tolentino et al., 2002; Pe’er et al., 1998; Vinores
et al., 1997). In addition, VEGF injections into the vitreous
of a nonhuman primate eye resulted in a CRVO-like appear-
ance characterized by retinal ischemia, intraretinal hemor-
rhages, and retinal edema (Tolentino et al., 2002). If VEGF
is responsible for the ME in CRVO, then one strategy would
be to treat the ME by inhibiting VEGF with an anti-VEGF
drug such as bevacizumab (Avastin, Genentech, Inc., San
Francisco, CA), a full-length, humanized, monoclonal anti-
body directed against VEGF.
In May 2005 at the Bascom Palmer Eye Institute, bev-
acizumab was ﬁrst injected into the vitreous of an eye withME from CRVO (Rosenfeld et al., 2005). Within 1 week of
the bevacizumab injection, the patient’s VA improved from
20/200 to 20/50 and optical coherence tomography (OCT)
imaging showed resolution of the cystic maculopathy charac-
teristic of ME. Since this initial report, intravitreal bev-
acizumab has been used with increasing regularity as the
primary pharmacotherapy for CRVO at the Bascom Palmer
Eye Institute. Intravitreal bevacizumab for vein occlusions is
now being used worldwide and multiple small case series with
short follow-up have already been reported (Costa et al., 2007;
Ferrara et al., 2007).
A number of recent studies have shown promising short-
term effects of bevacizumab when used for ME associated with
BRVO or central retinal vein occlusion (Kriechbaum et al.,
2008; Moschos and Moschos, 2008; Hsu et al., 2007; Matsum-
oto et al., 2007; Iturralde et al., 2006). After intravitreal injec-
tion of bevacizumab, optical coherence tomography (OCT)
demonstrates an immediate reduction in foveal thickness and
an improved visual acuity. In most reports, the morphologic
effect of bevacizumab was studied based on foveal thickness
measured by OCT and visual function evaluated by visual acu-
ity measurement.
In our study intravitreal Avastin (IVA) injection was used
as a primary treatment for RVOs and it was noticed that visual
acuity and CRT improved after a relatively short time within
1 week after ﬁrst IVA injection in which visual acuity im-
proved from mean of 20/240 or 1.08 (±0.52) log MAR at
baseline to 20/50 or 0.40 (±0.25) log MAR which it was statis-
tically signiﬁcant P< 0.0001. CMT improved also, from mean
of 455 lm (±126) SD {range, 386–510} at baseline to 280 lm
(±72) SD {range, 240–340} with a difference of 175 lm within
1 week. This improvement in both of visual acuity and CRT
lasted for about 6 weeks then, started to deteriorate again with
need for re-injection. However there is a variation from 1 pa-
tient to another in which 2 eyes with BRVO cured by one IVA
injection only while others with CRVO showed recurrence
with need for 5–6 re-injections. The response for improvement
and recurrence depend of degree of macular ischemia, amount
of retinal hemorrhages, extend of irreversible photoreceptor
damage and progression over time from perfused to nonper-
fused RVOs.
In the current study, all eyes either with CRVO or BRVO
showed improvement and some showed recurrence and re-
injection with stability of visual acuity and absence of ME,
mean CRT was 250 lm (±48) {range, 200–298} with maxi-
mum difference than the mean baseline in which it was
205 lm difference at the end of follow-up with mean visual
acuity of 20/60 or 0.48 (±0.32) log MAR indicating great use-
fulness of IVA in management of RVOs.
Our results in agreement with the results of Noritatsu et al.
(2009), in which they studied prospectively IVA injection in 20
eyes of 20 patients with RVOs (6 patients with CRVO and 14
with BRVO) in which the CRT decreased from mean of
560 lm (±123) at baseline to 391 lm (±145) after 6 months
of repeated injections. Also, our results in agreement with
Sherif (2008), in which he studied IVA injection in 15 eyes
of 15 patients with RVOs (10 eyes with CRVO and 5 with
BRVO) in which the CRT decreased from mean of 625 lm
at baseline to 200 lm after 12 months of repeated injections
and improvement of visual acuity from 20/100 at baseline to
20/40 at the end of 12 months follow-up. Our mean number
of IVA injection was 2.7 in agreement with Sherif’s results
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up in spite of he used higher dose of 0.1 ml (2.50 mg) that is
double our dose.
No intraocular or systemic adverse effects were reported in
our study during the 12 months of follow-up such as increased
intraocular pressure (IOP), retinal tear, retinal detachment, in-
duced cataract formation, inﬂammation, infection, systemic
hypertension or thromboembolic events and hence IVA seems
to be safe and effective in treatment of RVOs. Limitations of
the current study are relatively short-term follow-up, small
sample size, and lack of a control group.
In conclusion, despite these promising results there are
some risks of intravitreal injection of bevacizumab, further
long term randomized prospective controlled large studies
are necessary to conﬁrm the efﬁcacy of bevacizumab and to
determine the ideal protocol for this promising recent
treatment.
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